Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
558 stopped studies mapped to Acute Myeloid Leukemia and descendants · 90% state a reason
Over the 558 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03516760 | Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | Phase 1 | terminated | May 4, 2018 | AvenCell Europe GmbH | The actions and measures to be taken to restart the trial could not be implemented which made the… | Other (stated, no rule matched) |
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | Phase 2 | withdrawn | Feb 24, 2020 | Baptist Health South Florida | Study was split into two new studies before the first participant was enrolled. | Enrollment / accrual |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory… | Phase 1 | terminated | Jul 14, 2017 | AstraZeneca | Sponsor Decision | Sponsor / business decision |
| NCT04425655 | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed… | Phase 2 | terminated | Jun 11, 2020 | University of California, San Diego | Original investigator for the trial has left | Investigator |
| NCT04272203 | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose… | Phase 1 | terminated | Feb 17, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02267863 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | Phase 1 | terminated | Oct 20, 2014 | Aptose Biosciences Inc. | Drug manufacturing process and procedure review | Drug supply |
| NCT04006496 | AML Expressive Writing | N/A | terminated | Jul 5, 2019 | Duke University | Recruitment issues due to COVID-19 pandemic. | COVID-19 / pandemic |
| NCT03760666 | A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Nov 30, 2018 | Clear Creek Bio, Inc. | No efficacy observed, COVID-19 caused sites to shut down | COVID-19 / pandemic |
| NCT02773732 | Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute… | Phase 1 / Phase 2 | terminated | May 16, 2016 | University of Florida | slow enrollment | Enrollment / accrual |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2012 | Roswell Park Cancer Institute | Sponsor wanted study rewritten | Other (stated, no rule matched) |
| NCT05001451 | Study of GDX012 in Patients With MRD Positive AML | Phase 1 | terminated | Aug 12, 2021 | GammaDelta Therapeutics Limited | This was a business decision to discontinue this clinical trial. The decision is not related to the… | Safety / toxicity |
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | Phase 2 | terminated | Jan 23, 2013 | Dana-Farber Cancer Institute | Recommendation by the Data and Safety Monitoring Board due to efficacy concerns | Safety / toxicity |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jul 13, 2012 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT00961142 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity…(CD3/CD19 Haplo) | Phase 2 | terminated | Aug 18, 2009 | University Hospital Tuebingen | slow recruitment | Enrollment / accrual |
| NCT04093505 | Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients…(GnG) | Phase 3 | terminated | Sep 18, 2019 | University Hospital Heidelberg | Study turned out no longer feasible. End of Recruitment: 25.5.2022 | Enrollment / accrual |
| NCT01177540 | Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in… | Phase 2 | terminated | Aug 9, 2010 | Eisai Inc. | The study was terminated early due to enrollment difficulties and the futility of observing… | Efficacy / futility |
| NCT03850535 | A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine… | Phase 1 / Phase 2 | terminated | Feb 21, 2019 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. | Sponsor / business decision |
| NCT04326439 | AflacLL1901 (CHOA-AML) | Phase 2 | terminated | Mar 30, 2020 | Emory University | Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial;… | Enrollment / accrual |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic…(HERKULES-4) | Phase 1 / Phase 2 | withdrawn | Mar 15, 2022 | Erasca, Inc. | Sponsor decision. | Sponsor / business decision |
| NCT04655391 | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute… | Phase 1 | withdrawn | Dec 7, 2020 | City of Hope Medical Center | Drug availability | Drug supply |
| NCT03063203 | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Feb 24, 2017 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT04676243 | Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in…(Q-SOC) | Phase 3 | withdrawn | Dec 19, 2020 | University Hospital Heidelberg | Study turned out no longer feasible | Other (stated, no rule matched) |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation…(HATCY) | Phase 3 | terminated | Dec 21, 2016 | Kiadis Pharma | Insufficient efficacy, terminated by Sponsor | Efficacy / futility |
| NCT03552029 | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia… | Phase 1 | terminated | Jun 11, 2018 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | Phase 2 | terminated | Aug 31, 2009 | Wake Forest University Health Sciences | Sponsor/ PI leaving institution, no plans to continue this research at this time | Other (stated, no rule matched) |
| NCT02927938 | Leukemia Stem Cell Detection in Acute Myeloid Leukemia | Phase 3 | terminated | Oct 7, 2016 | Wake Forest University Health Sciences | Study terminated 7/23/2019 due to limited participation and testing challenges. | Other (stated, no rule matched) |
| NCT03600909 | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients… | Phase 2 | terminated | Jul 26, 2018 | Memorial Sloan Kettering Cancer Center | Accrual has been slow | Enrollment / accrual |
| NCT04858594 | Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy | — | terminated | Apr 26, 2021 | Masonic Cancer Center, University of Minnesota | PI left and research was stopped | Investigator |
| NCT03217838 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as… | Phase 1 | terminated | Jul 14, 2017 | AstraZeneca | strategic decision | Sponsor / business decision |
| NCT01187810 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | Phase 1 | terminated | Aug 24, 2010 | South Plains Oncology Consortium | drug supply | Drug supply |
| NCT01876953 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jun 13, 2013 | City of Hope Medical Center | Due to the budget issues, the study discontinued at Phase II. | Funding |
| NCT04893915 | Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS | Phase 2 | withdrawn | May 20, 2021 | Washington University School of Medicine | No funding support | Funding |
| NCT03151408 | An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults… | Phase 3 | terminated | May 12, 2017 | Helsinn Healthcare SA | The IDMC recommended to stop the study prematurely due to a lack of efficacy. | Efficacy / futility |
| NCT03696537 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | Phase 1 | terminated | Oct 4, 2018 | Naoyuki G. Saito, M.D., Ph.D. | Extreme toxicity | Safety / toxicity |
| NCT03922477 | A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in… | Phase 1 | terminated | Apr 22, 2019 | Hoffmann-La Roche | The Sponsor decided to discontinue the development of atezolizumab in combination with magrolimab… | Sponsor / business decision |
| NCT03761069 | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias | Phase 1 | terminated | Dec 3, 2018 | PTC Therapeutics | Sponsor terminated the study. | Other (stated, no rule matched) |
| NCT03951961 | Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After… | Phase 2 | terminated | May 16, 2019 | University of Jena | Insufficient Recruitment | Enrollment / accrual |
| NCT04044209 | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade… | Phase 2 | withdrawn | Aug 5, 2019 | Yale University | No patients were able to be screened nor enrolled. | Enrollment / accrual |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | Phase 1 / Phase 2 | terminated | Sep 20, 2019 | AGC Biologics S.p.A. | Inability to close the study in a clinically relevant time frame | Other (stated, no rule matched) |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic… | Phase 1 | terminated | Jan 9, 2019 | AbbVie | Safety | Safety / toxicity |
| NCT03557970 | JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Jun 15, 2018 | OHSU Knight Cancer Institute | Not enough enrollment to determine efficacy | Efficacy / futility |
| NCT04973618 | Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML | Phase 1 | withdrawn | Jul 22, 2021 | Aptevo Therapeutics | Change of strategy | Sponsor / business decision |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With… | Phase 1 | terminated | May 9, 2018 | University of Southern California | Study drug supply issue | Drug supply |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute… | Phase 1 / Phase 2 | terminated | Jun 10, 2016 | OncoTherapy Science, Inc. | slow patient accrual | Enrollment / accrual |
| NCT01620216 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic… | Phase 2 | terminated | Jun 15, 2012 | OHSU Knight Cancer Institute | Unable to recruit enough eligible subjects | Enrollment / accrual |
| NCT02770820 | Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly… | Phase 1 / Phase 2 | terminated | May 12, 2016 | Fred Hutchinson Cancer Center | Terminated due to funding difficulties | Funding |
| NCT04051996 | GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older… | Phase 2 | terminated | Aug 9, 2019 | Yale University | Unable to accrue patients following COVID-19 study pause. | COVID-19 / pandemic |
| NCT00766779 | HCT Versus CT in Elderly AML | Phase 3 | terminated | Oct 6, 2008 | European Society for Blood and Marrow Transplantation | Recommendation of DMC | Other (stated, no rule matched) |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine… | Phase 1 | terminated | Dec 18, 2014 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 29, 2022source: clinicaltrials